Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
German shepherds take down bad guys, dalmatians pull people from fires, beagles sniff out bombs and now llamas fight COVID-19.
Five months after Be Biopharma launched with $52 million in Series A financing, the company tapped bluebird bio veteran Joanne Smith-Farrell as its new chief executive officer.
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
Cambridge-based Bicara Therapeutics launched with a $40 million investment from its parent company, Biocon, to advance its bifunctional antibodies targeting both tumors and the immune system in cancer patients who are refractory to checkpoint inhibitors.
Aron Knickerbocker, former Chief Executive Officer (CEO) of RayzeBio and Five Prime Therapeutics, has taken the helm of Aulos Bioscience, a relatively new biotech company focused on the development of highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies the treatment of solid tumors.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
Two of the biggest drugmakers in the HIV space are teaming up on a combination therapy that has the potential to be a game-changer for patients diagnosed with the dangerous virus for which there is no known cure.
Today, AVEO Oncology announced it had inked a clinical trial collaboration and supply deal with Bristol Myers Squibb to study Fotivda in combination with BMS’s checkpoint inhibitor Opdivo in advanced r/r RCC after previous immunotherapy exposure.
The two pharmaceutical companies are going public and anticipate raising more than $250 million to advance research and development programs and support their business initiatives.